Richard A. Marlar, Ph.D.

photo of richard marlar

Volunteer Professor

Email: RMarlar@salud.unm.edu


Interests:

  • Thrombophilia Testing
  • Protein C and Protein S Deficiencies
  • Concept of “Deficiency” in Hemostasis
  • Quality Assurance Issues in Thrombosis and Hemostasis

Education and Certification Information

Fellowship:
NIH and AHA Fellowships
Biochemistry of Hemostasis
Mentor, John H. Griffin
Scripps Clinic and Research Institutes
La Jolla, CA
1981

PhD (Physiology and Biochemistry):
Wayne State University
Mentor, Dr. Walter H. Seegers
Detroit, MI
1978

MS:
MS (Zoology and Chemistry)
University of North Dakota
Grand Forks, ND
1974

BSc:
BSc (Zoology)
Humboldt State University
Arcata, CA
1972


Selected Publications:

  • Marlar RA, Gausman JN. Assessment of hereditary thrombophilia - Performance of Protein C (PC) testing. In: Haemostasis and Thrombosis: Methods and Protocols, Eds: Favaloro & Lippi. New York; Springer, 2016.

  • Marlar RA, Clement B, Gausman J. APTT monitoring of Unfractionated Heparin therapy: Issues and Recommendations. Sem Thromb Hemost, e-publication, 2016.

  • Brisset AC, Fernandez A, Krause M, Rathbun S, Marlar R, Korte W. The PiCT® test, a reliable alternative to the aPTT in UFH therapy management – results from a prospective multicenter cohort study. J Thromb Hemost, 14:1-7, 2016.

  • Rathbun S, Tafur A, Grant R, Esmon N, Mauer K, Marlar RA: Comparison of methods to determine rivaroxaban anti-factor Xa activity. Thromb Res 125:394-397, 2015.

  • Marlar RA, Gausman JN: Laboratory testing issues for protein C, protein S, and antithrombin. Internat J Lab Hem 36:289-295, 2014.

  • Marlar RA, Gausman JN, Engel JW: Validation of hemostasis and coagulation assays: Recommendations and guidelines. Sem Thromb Hemost 40:186-195, 2014.

  • Johnson PN, Benefield EC, Phi-Yen NB, Gausman JN, Marlar RA, Gessouroun MR: Fondaparinux monitoring: Need for a local fondaparinux-calibrated anti-factor Xa assay. J Ped Pharmacol Therap. 18:318-319, 2013

  • Marlar RA: Hemostasis Test Validation, Performance and Reference Intervals. Chapter 2. In: Olson J, Kitchen S, Preston E, eds. Quality in Laboratory Hemostasis and Thrombosis. Blackwell Publishers, 2nd edition, 2013.

  • Marlar RA, Gausman JN: The optimum number and types of plasma samples necessary for an accurate APTT-based heparin therapeutic range. Arch Path Lab Med 137(1):77-82, 2013.

  • Marlar RA, Seywerd K: Laboratory Evaluation of Acquired Coagulation Disorders. In: Kottke-Merchant K. and Davis B., eds. Laboratory Hematology Practice, Wiley-Blackwell Press, Chapter 37, 2012.

  • Marlar RA: Are laboratory results (phenotype) indicative of a true genotype abnormality? Am J Clin Path 137:173-175, 2012.

  • Marlar RA, Gausman JN: Protein S abnormalities: A diagnostic nightmare. Am J Hematol 86:418-421, 2011.

  • Marlar RA: Accurate testing of dysfunctional molecules: Potential for missing the diagnosis. Int J Lab Hematol 33:451-453, 2011.

  • Gausman JN, Marlar RA: Inaccuracy of a ‘spiked curve’ for monitoring unfractionated heparin therapy. Am J Clin Path 135:870-876, 2011.

  • Marlar RA, Fink L, Miller J: Laboratory approach to thrombotic risk. In: Henry’s Clinical Diagnosis and Management by Laboratory Methods, 22nd edition, Eds: McPherson and Pincus, New York, Saunders, chapter 41, 2011.

Search PubMed:

Richard A. Marlar on PubMed